Refine by
Oncology Technology Serving Libya
22 companies found
Technologybased inCambridge, MASSACHUSETTS (USA)
Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will be fundamental to help the world in rethinking what's ...
Technologybased inLouvain-La-Neuve, BELGIUM
At IBA we dare to develop innovative solutions pushing back the limits of technology. We share ideas and know-how with our customers and our partners to bring new solutions for the diagnosis and treatment of cancer. We care about the well-being of ...
Proteus® has been inspired by everyday clinical practice. Through day-to-day interactions with the community, IBA is perfectly positioned to understand, and invest in, the user’s needs. These investments are directly translated into ...
Technologybased inMelbourne, AUSTRALIA
Starpharma Holdings Limited is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery and ...
DEP® irinotecan is an improved version of irinotecan (Camptosar®), predominantly used for colorectal cancer. DEP® irinotecan is a novel, patented nanoparticle formulation of SN-38, the active metabolite of irinotecan, delivered using ...
Technologybased inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
Technologybased inAustin, TEXAS (USA)
Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more ...
Why partner with Signatera for your clinical trial? Clinically validated across multiple solid tumors, Signatera has shown to predict relapse in >98% of patients without further treatment. Experienced team with Global reach: CE Mark, three FDA ...
Technologybased inCambridge, MASSACHUSETTS (USA)
Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, ...
Technologybased inChicago, ILLINOIS (USA)
GE HealthCare operates as a leader in precision care, integrating advanced technologies with patient-focused solutions to enhance healthcare delivery. The company invests approximately $1 billion annually in research and development, focusing on ...
Technologybased inStockholm, SWEDEN
RaySearch® is advancing cancer treatment through pioneering software. Software has unlimited potential, and it is now the driving force for innovation in oncology. Medical science never stands still and neither does RaySearch. We work in close ...
Iterative parameter tuning and multiple re-optimization is no longer necessary with multi-criteria optimization in RayStation. This module allows for the continuous exploration of the possible treatment options in real time so you can find ...
Technologybased inLYON, FRANCE
Founded in December 2013, Adjuvatis is specialized in the development, manufacturing and formulation of a safe-by-design delivery system, called i-Particles®. Based on fully metabolizable ans biocompatible particles, this technology was initially ...
Technologybased inLondon, UNITED KINGDOM
Founded in 2015, the original idea behind Airfinity was to systematically capture and structure the new science disseminated at conferences, a highly fragmented dataset. However, through working with medical associations and pharma companies, ...
Technologybased inSeoul, SOUTH KOREA
GI Innovation is a bio-venture company that researches and develops innovative protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and ...
Promotes the generation of cancer-specific effector T cell (Teff) in lymph nodes, and induces the activation and proliferation of tumor-infiltrating Teff and NK cells. Controls the immuno-suppressive function of regulatory T cells (Tregs) in tumor ...
Technologybased inBoston, MASSACHUSETTS (USA)
We can create human tissues and organs using cells from our own bodies, paving the way to make us our own organ donors, reducing organ rejection and solve the problem with lack of donors. We can save lives with faster and more accurate methods for ...
The high-throughput, fully automated biodispensing solution that leverages BIOPOD (bioprinting on demand) technology with pre-set and pre-validated protocols to bring the power of 3D cell biology to your ...
Technologybased inRegensburg, GERMANY
numares is an innovative diagnostics company. We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet medical needs that could not be addressed by single biomarker-based ...
Cancer is among the leading causes of death worldwide. Approximately 38 % of men and women will be diagnosed with cancer at some point during their lifetimes (based on 2013 – 2015 data1). Cancer can occur in any organ and in any cell ...
Technologybased inOttawa, SWITZERLAND
Orion Biotechnology is unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules. The company is advancing a diversified ...
G Protein-Coupled Receptors (GPCRs) are involved in a wide range of physiological and pathological processes and represent a large class of drug targets accounting for >30% of all drugs on the market. These drugs, however, only cover 15% of the ...
Technologybased inMonroe Township, NEW JERSEY (USA)
We are a multinational company active in the life science sector, a world leader in imaging diagnostics. Every day we seek and perfect increasingly advanced and sustainable techniques and solutions to open new paths in diagnostic imaging. So that ...
Technologybased inMilan, ITALY
Italfarmaco SpA is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries through its controlled and/or participated companies. Italfarmaco was establish in ...
MYELOSTIM® (lenograstim) is the only glycosylated granulocyte growth factor, indistinguishable from the native human one, effectively enabling to prevent and control bone marrow toxicity caused by the use of chemotherapeutic agents producing ...
Technologybased inNangang Distric, TAIWAN
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ...
TLC is using antibodies and antibody fragments attached to lipid encapsulated drugs to develop more effective therapies in oncology. These antibody-linked nanomedicines actively target specific tissues using binding interactions ...
Technologybased inWichita, KANSAS (USA)
Neotherma Oncology is led by experienced healthcare executives who are working toward the dream of more effective treatments for cancer. NeoTherma Oncology is developing a groundbreaking type of radio frequency (RF) thermal treatment for deep solid ...
NeoTherma Oncology is a clinical stage medical device company developing a proprietary Thermal Treatment (VectRx) system for deep solid tumors. Our technology is based on applying a safe, non-invasive, non-ionizing electromagnetic ...
Technologybased inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
Technologybased inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
DSP-0390 is an emopamil-binding protein (EBP) inhibitor. EBP is an endoplasmic reticulum membrane protein involved in cholesterol biosynthesis.47 When functional, EBP mediates de novo cholesterol synthesis for cell membrane structure and signaling, ...